RemSleep Holdings (RMSL) Cash from Operations Growth (3y) (2013 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 4.78% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 9.30% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 20.35% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 22.35% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -48.14% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 0.50% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 50.11% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -14.75% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 15.83% |
| 10 | RemSleep Holdings | - | - | -7,636.00 | 21.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 21.87% |
| Sep 30, 2025 | 18.19% |
| Jun 30, 2025 | 54.91% |
| Mar 31, 2025 | 17.92% |
| Dec 31, 2024 | -21.71% |
| Sep 30, 2024 | -61.92% |
| Jun 30, 2024 | -2.26% |
| Mar 31, 2024 | -21.55% |
| Dec 31, 2023 | -41.30% |
| Sep 30, 2023 | -60.03% |
| Jun 30, 2023 | -25.19% |
| Mar 31, 2023 | -22.90% |
| Dec 31, 2022 | -46.81% |
| Sep 30, 2022 | -62.57% |
| Jun 30, 2022 | -201.23% |
| Mar 31, 2022 | -67.95% |
| Dec 31, 2021 | -54.02% |
| Sep 30, 2021 | -36.57% |
| Jun 30, 2021 | -56.50% |
| Mar 31, 2021 | -32.35% |
| Dec 31, 2020 | -39.17% |
| Sep 30, 2020 | -23.45% |
| Jun 30, 2020 | -71.73% |
| Mar 31, 2020 | -58.64% |
| Dec 31, 2019 | 7.13% |
| Sep 30, 2019 | -168.52% |
| Jun 30, 2019 | -164.19% |
| Mar 31, 2019 | -17.31% |
| Dec 31, 2018 | -18.86% |
| Jun 30, 2018 | 1.16% |
| Mar 31, 2018 | 7.05% |
| Dec 31, 2017 | 36.13% |
| Dec 31, 2016 | -249.51% |
| Sep 30, 2016 | 40.03% |
| Jun 30, 2016 | 84.82% |
| Mar 31, 2016 | -392.22% |
| Dec 31, 2015 | 40.78% |
| Jun 30, 2015 | 86.64% |
| Mar 31, 2015 | -25.29% |
| Dec 31, 2014 | -11.12% |
| Dec 31, 2013 | 76.27% |
| Sep 30, 2013 | 77.05% |